Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

It’s back to school for biotech, with a packed conference schedule.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.

The 2024 AACR abstract title drop features several noteworthy clinical studies.

Despite magrolimab’s latest flop, efforts to target CD47 continue.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.